Medline Slides as FDA Warning, Fire Fallout and Share-Supply Overhang Weigh on Sentiment

Medline Inc. (MDLN) is down 5.0% today. Here is some analysis on what might have caused this price movement.

Analysis: A single fresh catalyst is not obvious, so the decline appears tied to lingering pressure from Medline’s regulatory and operational issues. This could be because investors are still weighing a serious FDA warning letter, the fallout from the June destruction of a major California warehouse, and the stock overhang created by large secondary sales from existing holders.

Details:

The FDA issued a warning letter on May 28 describing contamination-control and investigation failures at a Medline drug manufacturing facility, including repeated concerns tied to microbial findings and corrective actions that regulators viewed as inadequate.

Medline’s Northern California distribution network was disrupted after its Tracy warehouse was destroyed by fire on June 11, creating concerns about near-term logistics even though the company later moved to secure replacement space.

On July 6, Medline said it had leased more than 1.6 million square feet of new distribution capacity in Tracy and Stockton, which helps the recovery effort but also highlights how significant the disruption had been.

Investor sentiment has also been pressured by large secondary stock offerings completed in March and May, which increased share supply and may have limited buyers’ willingness to step in during a weak session.

Sources:

FDA, Medline Investor Relations, Medline Newsroom, Globe Newswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDLN Insider Trading Activity

$MDLN insiders have traded $MDLN stock on the open market 31 times in the past 6 months. Of those trades, 1 have been purchases and 30 have been sales.

Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:

8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 8 sales selling 61,170,810 shares for an estimated $2,345,618,751.
MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 8 sales selling 61,170,810 shares for an estimated $2,345,618,751.
& FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 8 sales selling 57,999,474 shares for an estimated $2,222,909,857.
GROUP CAYMAN INVESTMENT HOLDINGS, L.P. TC sold 26,105,840 shares for an estimated $1,070,339,440
GROUP INC. CARLYLE sold 26,105,840 shares for an estimated $1,070,339,440
MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE sold 26,105,840 shares for an estimated $1,070,339,440
CIRCLE ML HOLDCO GP, LLC CP sold 26,105,840 shares for an estimated $1,070,339,440
DOUGLAS P GOLWAS (Chief Commercial Officer) has made 0 purchases and 2 sales selling 100,000 shares for an estimated $3,677,115.
JESSI L CORCORAN (Principal Accounting Officer) purchased 5,000 shares for an estimated $170,750

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MDLN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MDLN Hedge Fund Activity

We have seen 234 institutional investors add shares of $MDLN stock to their portfolio, and 63 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

H&F CORPORATE INVESTORS X, LTD. removed 13,040,572 shares (-13.1%) from their portfolio in Q1 2026, for an estimated $580,305,454
FMR LLC added 10,201,987 shares (+38.7%) to their portfolio in Q1 2026, for an estimated $453,988,421
CAPITAL RESEARCH GLOBAL INVESTORS added 8,377,467 shares (+56.7%) to their portfolio in Q1 2026, for an estimated $372,797,281
SURGOCAP PARTNERS LP added 6,075,165 shares (+inf%) to their portfolio in Q1 2026, for an estimated $270,344,842
BLACKROCK, INC. added 5,410,710 shares (+47.0%) to their portfolio in Q1 2026, for an estimated $240,776,595
VIKING GLOBAL INVESTORS LP added 4,474,835 shares (+64.3%) to their portfolio in Q1 2026, for an estimated $199,130,157
CITADEL ADVISORS LLC removed 4,412,981 shares (-73.5%) from their portfolio in Q1 2026, for an estimated $196,377,654

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDLN Analyst Ratings

Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Tigress Financial issued a "Buy" rating on 05/13/2026
BTIG issued a "Buy" rating on 01/12/2026
RBC Capital issued a "Outperform" rating on 01/12/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Wolfe Research issued a "Outperform" rating on 01/12/2026
Barclays issued a "Overweight" rating on 01/12/2026
Citigroup issued a "Buy" rating on 01/12/2026

To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.

$MDLN Price Targets

Multiple analysts have issued price targets for $MDLN recently. We have seen 24 analysts offer price targets for $MDLN in the last 6 months, with a median target of $49.5.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $45.0 on 06/03/2026
Glen Santangelo from Barclays set a target price of $45.0 on 06/01/2026
Navann Ty from BNP Paribas set a target price of $40.0 on 05/14/2026
Ivan Feinseth from Tigress Financial set a target price of $62.0 on 05/13/2026
David Larsen from BTIG set a target price of $55.0 on 05/07/2026
Lee Hambright from Bernstein set a target price of $54.0 on 05/07/2026
Patrick Donnelly from Citigroup set a target price of $55.0 on 05/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.